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Transcatheter Closure of Fontan Fenestrations Using
the Amplatzer Septal Occluder: Initial Experience
and Follow-Up
Collin G. Cowley, MD, Sarah Badran, MD, Diane Gaffney, Albert P. Rocchini, MD,
and Thomas R. Lloyd,* MD
We have recently used the Amplatzer septal occluder to close Fontan fenestrations.
Between June 1998 and December 1999, 13 patients underwent transcatheter occlusion
of their Fontan fenestrations. Systemic blood flow decreased significantly without a
concomitant decrease in pulmonary blood flow. All residual shunts detectable by oxim-
etry were at sites separate from those into which occlusion devices were implanted. One
patient developed severe tricuspid regurgitation following the procedure requiring sur-
gical removal of the device. At the last follow-up, all patients were doing well clinically.
There were no shunts detectable through or around the devices by echocardiography.
Our experience indicates that the location of the fenestration within the Fontan baffle is
critical to avoiding device interference with other intracardiac structures. The Amplatzer
septal occluder offers an effective means of transcatheter closure of Fontan baffle
fenestrations. Although more experience is needed, our current follow-up data suggest
that long-term outcomes will be favorable. Cathet. Cardiovasc. Intervent. 51:301–304,
2000. © 2000 Wiley-Liss, Inc.
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INTRODUCTION
Fontan baffle fenestration allows right-to-left shunting
that enhances cardiac output during the postoperative
period, limits systemic venous pressure, and may help to
reduce the accumulation of pleural fluid [1,2]. The major
indication for baffle fenestration closure is to eliminate
the risks of long-term right-to-left shunting. In addition
to the use of surgically placed abdominal snares [1,3], a
variety of transcatheter approaches to fenestration clo-
sure have been described [4–7]. The newly developed
Amplatzer septal occluder (AGA Medical, Golden Val-
ley, MN) offers an alternative to other currently available
devices. This study describes our initial experience and
follow-up evaluation in 13 patients with transcatheter




Amplatzer septal occluders were implanted under a
protocol approved by the University of Michigan Medi-
cal School institutional review board. Study subjects had
previously undergone a lateral tunnel Fontan procedure
using Goretex (W.L. Gore & Associates, Flagstaff, AZ)
with a 4-mm fenestration created using a standard punch.
We reviewed the records of all patients enrolled in this
protocol for the purpose of Fontan fenestration occlusion
from June 1998 through December 1999. Patient sex,
age, weight, and native cardiac anatomy were noted, as
well as the time interval between the fenestrated Fontan
operation and fenestration occlusion. Cardiac catheter-
ization data included mean pressure and oxygen satura-
tions in the Fontan baffle and aorta before and after
fenestration occlusion. Pulmonary vein oxygen satura-
tion was measured before occlusion and was assumed to
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be unchanged after occlusion. The ratio of pulmonary to
systemic blood flow before and after fenestration closure
was calculated assuming a constant oxygen consumption
and neglecting shunting through collateral arteries [3].
Cineangiography within the baffle was performed before
and after fenestration occlusion (Fig. 1). Follow-up data
included duration of follow-up, pulse oximetry values,
chest X-ray determination of device dimensions, and any
interval complications. Device dimensions were mea-
sured from tip to tip on chest X-rays obtained at 24 hr as
compared to subsequent chest X-rays obtained at the
most recent follow-up. Echocardiographic data included
presence and sites of baffle shunting, presence of throm-
bus, flow disturbance within the baffle, or device inter-
ference with the tricuspid valve or other intracardiac
structures. Continuous data are presented as mean6
standard deviation. Pairedt-tests were used to compare
data before and after fenestration occlusion.
Closure Protocol
Cardiac catheterization for Fontan fenestration closure
was performed using general endotracheal anesthesia,
systemic heparinization, and antimicrobial prophylaxis
using intravenous cefazolin (25 mg/kg). Cineangiogra-
phy was performed in the Fontan baffle to evaluate
pulmonary artery anatomy, fenestration location, and po-
tential additional sites of intracardiac shunting. The fen-
estration size was determined through the use of a stan-
dard sizing balloon. The Amplatzer delivery sheath (6 or
7 Fr) was placed through the fenestration over a guide-
wire. Under transesophageal echocardiographic and stan-
dard biplane fluoroscopic guidance, the device was po-
sitioned and released as previously described [8].
Hemodynamic measurements and cineangiography of
the Fontan baffle were repeated after occlusion. Patients
recovered overnight in the hospital, and two additional
doses of intravenous cefazolin (25 mg/kg) were given at
8-hr intervals. A chest X-ray, electrocardiogram, and
transthoracic echocardiogram were performed prior to
patient discharge. As dictated by the study protocol,
aspirin (81 mg/day) was prescribed for 6 months. Rou-
tine follow-up evaluation was scheduled at 6 and 12
months following device implantation.
RESULTS
The Amplatzer septal occluder was successfully deliv-
ered in all 13 patients attempted with one major compli-
cation as described below. Table I summarizes patient
and procedure details. Transhepatic access was required
in four patients due to femoral vein occlusion (n5 3) or
congenital interruption of the inferior vena cava (n5 1).
The patient who received two Amplatzer occluders had
three discrete sites of baffle shunting and had devices
mplanted into the two larger defects with no attempt
made to occlude the smallest defect. The hemodynamic
data are summarized in Table II. Arterial oxygen satura-
tion and the ratio of pulmonary to systemic blood flow
increased significantly while mixed venous saturation
Fig. 1. (A) Contrast injection demonstrates right to left shunt-
ing across the Fontan fenestration. (B) Following placement of
the Amplatzer septal occluder, no residual shunt is detected.
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was unchanged. Consequently, a significant decrease in
systemic blood flow was calculated (25%6 16%, P 5
0.0005) without a significant decrease in pulmonary
blood flow (5%6 15%, P 5 0.16). All residual shunts
detectable by oximetry were at sites separate from those
into which occlusion devices were implanted, typically
through intramyocardial channels. Average tip-to-tip di-
mensions decreased by 13% in the seven patients in
whom follow-up X-rays were available for review. The
average dimension decreased from 13.96 1.6 mm to
12.16 1.1 mm,P 5 0.009).
Complications
Three patients had complications from the procedure.
In one patient, left-sided atrial fibrin-like strands were
detected by echocardiography, but no clinical sequelae
were evident. One patient developed bleeding at the
femoral vascular access site during recovery, which was
controlled with direct pressure. Blood transfusion was
not necessary. One patient developed severe tricuspid
regurgitation 2 days following the procedure requiring
surgical removal of the device. Upon direct examination,
the fenestration site was very close to the valve appara-
tus, allowing the device to entrap portions of the anterior
and septal leaflets. Transesophageal echocardiography
during implantation and transthoracic echocardiography
1 day following the procedure had shown no significant
tricuspid regurgitation and no interference of the device
with the tricuspid valve. The device was removed and a
small perforation was successfully repaired. This patient
has done well since.
Follow-Up
Follow-up data are summarized in Table III. The av-
erage time since the procedure was 10.4 months (range,
1.2–19.5 months). All patients were doing well clini-
cally. There were no shunts detectable through or around
the devices by transthoracic echocardiography. There
was also no evidence of thrombosis, baffle obstruction,
or new atrioventricular valve stenosis or insufficiency.
The average room air saturation was 95.3% in the nine
patients in whom these data were available at the last
follow-up, including the patient who had two devices






% systemic saturation 89.36 4.5 95.66 2.8 ,0.0001
% mixed venous
saturation 67.36 7.9 65.26 8.7 NS
Mean baffle pressure
(mm Hg) 11.66 2.4 12.76 1.9 NS
Mean systemic pressure
(mm Hg) 57.26 8.8 59.16 12.8 NS
Qp:Qs 0.776 0.12 0.976 0.06 ,0.0001
*NS, not significant; Qp:Qs, ratio of pulmonary to systemic blood flow.















size Residual shunt Additional interventions
3.8 14.5 2.1 2.2 15.8 Femoral 4 mm Trace (above
fenestration)
3.3 11.9 0.7 2.0 17.1 Femoral 4 mm Trace (above
fenestration)




3.2 13.2 0.8 3.6 13.1 Transhepatic 4 mm None
2.8 12.5 0.7 2.0 10.8 Femoral 4 mm Trace
3.2 13.6 1.5 3.4 46.4 Transhepatic 4 mm Trace (above
fenestration)
2.0 11.5 0.6 2.3 25.5 Femoral 4 mm None
3.0 15.0 0.9 2.0 9.7 Femoral 4 mm Trace (above
fenestration)
7.1 22.0 4.8 4.4 25.7 Femoral 7 mm Trace
2.4 14.3 0.8 2.3 12.2 Femoral 4 mm None Removal of broken snare
system
3.2 11.5 0.9 3.0 25.7 Transhepatic 4 mm None Balloon dilation of LPA
stent
2.1 11.5 0.6 2.5 19.1 Femoral 4 mm None Coil occlusion of LSVC
3.4 15.6 1.7 2.4 19.1 Femoral 4 mm None
Median 3.2 13.6 0.9 2.4 19.1
Mean6 SD 4.66 4.8 16.76 10.9 1.46 1.2 2.76 0.8 21.66 11.3
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placed and persistent shunting through a third site. The
patient who required surgical device removal and tricus-
pid valve repair suffered no apparent additional sequelae.
DISCUSSION
Fenestration of the Fontan baffle, although still con-
troversial [9], has been reported to improve mortality and
morbidity in patients undergoing Fontan palliation [4].
However, closure of these fenestrations requires an ad-
ditional surgical or catheter procedure. Our experience
with the Amplatzer septal occluder has shown that this
device effectively eliminates shunting through occluded
communications and yields immediate hemodynamic re-
sults that are identical to fenestration occlusion by snare
[3]. The Amplatzer device is easy to use, is easily re-
trieved prior to release, and can be implanted into Fontan
fenestrations with acceptable procedure length and radi-
ation time. The profile of the device does not appear to
alter blood flow through the baffle significantly. Al-
though the observed foreshortening of the device may
result from tissue ingrowth and contraction, whether or
not a device positioned within a synthetic baffle under-
goes subsequent endothelialization remains unknown.
Therefore, while the current protocol required aspirin
therapy for 6 months, some patients received additional
anticoagulation therapy at the discretion of their regular
cardiologist.
Aside from the patient who developed femoral bleed-
ing, the complications encountered early in this patient
series likely reflect the normal learning curve inherent to
any novel approach using new technology. Our experi-
ence emphasizes the importance of adequate hepariniza-
tion just prior to device delivery to avoid potential throm-
boembolic events. Our experience also indicates that in
addition to careful visualization via fluoroscopy and
echocardiography during device implantation, the loca-
tion of the fenestration within the Fontan baffle is critical
to avoiding device interference with other intracardiac
structures.
The Amplatzer septal occluder offers an effective
means of transcatheter closure of Fontan baffle fenestra-
tions. The device offers advantages in terms of ease of
use and retrievability prior to release compared to other
currently available devices. Although more experience is
needed, our current follow-up data suggest that long-term
outcomes will be favorable.
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Third site of right to left
shunt
13.3 N/A No baffle leak/obstruction
14.8 97 No baffle leak/obstruction
13.1 N/A No baffle leak/obstruction
7.3 98 No baffle leak/obstruction
6.8 93 No baffle leak/obstruction
6.4 91 No baffle leak/obstruction
6.5 98 No baffle leak/obstruction
5.7 98 No baffle leak/obstruction
1.2 98 N/A
N/A N/A N/A
Mean6 SD 10.46 5.5 956 3
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